Medizinische Klinik und Poliklinik III Abteilung für Hämatologie und Onkologie Universitätsklinikum Bonn
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wolf, Dominik
LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Recruiting
3
70
Europe
Luspatercept, Reblozyl
GWT-TUD GmbH, Celgene
Myelodysplastic Syndromes
12/24
06/25
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)
Chronic Lymphoid Leukemia
03/27
03/27
DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Recruiting
2
134
Europe
Dasatinib
Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn
CML, Relapsed
02/23
02/24
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting
2
53
Europe
Acalabrutinib, Calquence, ACP-196
German CLL Study Group
Chronic Lymphoid Leukemia
07/23
12/24
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
PALINDROM, NCT06172894: PBMC-based Leukocyte Immunotherapy

Recruiting
1
12
Europe
APN401
invIOs GmbH
Advanced Solid Tumor
03/24
03/24
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry

Recruiting
N/A
500
Europe
Arbeitsgemeinschaft medikamentoese Tumortherapie
Chronic Lymphocytic Leukemia
12/27
12/27
InflamGen, NCT04313231: Sterile Inflammation and Molecular Aberrations in MDS

Recruiting
N/A
130
Europe
Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry, Metagenomics of stool samples, Clinical/demographic data, Elicitation of the HRQoL
Medical University Innsbruck, University Hospital, Bonn, Universitätsklinikum Leipzig
Myelodysplastic Syndromes
01/23
01/23
PRO-RED, NCT05582902: Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Recruiting
N/A
60
Europe
University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany)
MDS, MDS/MPN
03/25
03/25

Download Options